These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 18590003)

  • 21. Immunogenetics of drug-induced skin blistering disorders. Part I: Perspective.
    Bowman C; Delrieu O
    Pharmacogenomics; 2009 Apr; 10(4):601-21. PubMed ID: 19374517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abacavir hypersensitivity.
    Vandekerckhove L; Blot S; Vogelaers D
    N Engl J Med; 2008 Jun; 358(23):2514-5; author reply 2515-6. PubMed ID: 18525052
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacogenomics of antimicrobial agents.
    Aung AK; Haas DW; Hulgan T; Phillips EJ
    Pharmacogenomics; 2014; 15(15):1903-30. PubMed ID: 25495412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA-B*5701 and abacavir hypersensitivity.
    Watson ME; Pimenta JM; Spreen WR; Hernandez JE
    Pharmacogenetics; 2004 Nov; 14(11):783-4; author reply 784. PubMed ID: 15564887
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug hypersensitivity in HIV.
    Phillips E; Mallal S
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):324-30. PubMed ID: 17620824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [HLA-B*5701 and abacavir hypersensitivity reaction].
    Servonnet A; Leclercq E; Delacour H; Ceppa F
    Pathol Biol (Paris); 2010 Dec; 58(6):e95-100. PubMed ID: 19243901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?
    Nolan D; Gaudieri S; Mallal S
    J HIV Ther; 2003 May; 8(2):36-41. PubMed ID: 12838163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The contribution of pharmacogenetics to pharmacovigilance.
    Bondon-Guitton E; Despas F; Becquemont L
    Therapie; 2016 Apr; 71(2):223-8. PubMed ID: 27080842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
    Park WB; Choe PG; Song KH; Lee S; Jang HC; Jeon JH; Park SW; Park MH; Oh MD; Choe KW
    Clin Infect Dis; 2009 Feb; 48(3):365-7. PubMed ID: 19115972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.
    Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T
    Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA and drug-induced toxicity.
    Phillips EJ; Mallal SA
    Curr Opin Mol Ther; 2009 Jun; 11(3):231-42. PubMed ID: 19479656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HLA-B*5701 screening for hypersensitivity to abacavir.
    Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
    N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
    Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
    Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies.
    Tonk ECM; Gurwitz D; Maitland-van der Zee AH; Janssens ACJW
    Pharmacogenomics J; 2017 Jul; 17(4):386-392. PubMed ID: 27168098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients.
    Parczewski M; Leszczyszyn-Pynka M; Wnuk A; Urbañska A; Fuksiñska K; Bander D; Boroñ-Kaczmarska A
    HIV Med; 2010 May; 11(5):345-8. PubMed ID: 20070406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Foreword. Drug allergy and primum non-nocere.
    Alam R
    Immunol Allergy Clin North Am; 2009 Aug; 29(3):xiii-xiv. PubMed ID: 19563986
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacogenetics: The right drug for you.
    Drew L
    Nature; 2016 Sep; 537(7619):S60-2. PubMed ID: 27602742
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful implementation of a national HLA-B*5701 genetic testing service in Canada.
    Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B
    Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.
    Martin AM; Krueger R; Almeida CA; Nolan D; Phillips E; Mallal S
    Pharmacogenet Genomics; 2006 May; 16(5):353-7. PubMed ID: 16609367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A fluorescence-based sequence-specific primer PCR for the screening of HLA-B(*)57:01.
    Giardina E; Stocchi L; Foti Cuzzola V; Zampatti S; Gambardella S; Patrizi MP; Bramanti P; Pirazzoli A; Novelli G
    Electrophoresis; 2010 Oct; 31(21):3525-30. PubMed ID: 20925049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.